CorMedix Defers DefenCath's 2027 Sales Forecast Even As It Expects Higher Reimbursement
Customer pricing and Medicare Advantage talks remain unfinished, while the company narrowed its 2026 adjusted earnings outlook.
CorMedix, which develops and sells treatments for life-threatening diseases, deferred its 2027 sales forecast for DefenCath on Thursday despite expecting higher reimbursement in every quarter next year. The earnings call, furnished in a Friday SEC filing, tied the delay to unresolved customer pricing, patient utilization and Medicare Advantage payments.
Higher Payments, Unfinished Pricing
Management expects the additional reimbursement for DefenCath to exceed the current $2.37 in each quarter of 2027. It estimates the annual average will be at least double that rate, though below the $8.32 payment set for the first quarter, according to the company's earnings call.
Medicare finalized a quarterly reset using recent pricing and utilization information. CorMedix expects reimbursement to fall in the second quarter, then rise in the third and/or fourth quarters, depending on how Medicare applies the methodology.
Customer prices are being negotiated to follow those quarterly changes, with the goal of keeping traditional Medicare patients on treatment. Chairman and CEO Joseph Todisco said rebate-payment timing can cause the pricing information used for reimbursement to differ from net prices reported in earnings.
Medicare Advantage offers another possible source of patients and revenue, but separate payment arrangements remain under negotiation. Todisco described a contractual framework as “largely final” and said implementation still needed agreement. He remained cautiously optimistic about reaching an arrangement before year-end.
DefenCath is a catheter lock solution that reduces catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis. It is CorMedix's largest net-sales contributor, sold mainly to outpatient dialysis clinics and hospitals. Management said its largest dialysis customers largely maintained utilization during the third quarter.
Sales Fall After Reimbursement Transition
Third-quarter revenue fell to $54.5 million from $104.3 million a year earlier. DefenCath generated $17.2 million, including a $5 million favorable revision to Medicaid rebate and product-return allowances; management attributed its sales decline primarily to lower net pricing following the July 1 reimbursement transition.
The rest of the portfolio contributed $37.3 million: $31.4 million in product sales and about $5.9 million in contract revenue and grant income under the BARDA agreement. Comparisons include a full quarter of Melinta operations in 2026 against only one month in 2025, following the August 29, 2025 acquisition.
Adjusted earnings before interest, taxes, depreciation and amortization fell to $3.1 million from $71.9 million. That measure excludes the favorable $5 million sales-allowance revision. The reported net loss was $14.7 million, including an $11.5 million noncash expense tied to Melinta contingent payments; year-earlier net income of $108.6 million included a $59.7 million tax benefit.
CorMedix maintained its 2026 revenue forecast of $325 million–$345 million. It narrowed its adjusted earnings outlook to $130 million–$140 million, the upper end of its previous range, and lowered and narrowed expected operating expenses excluding noncash items to $140 million–$145 million.
Quarter-end cash totaled $355.2 million. Operating cash flow for the first nine months rose to $218.3 million from $80.6 million, which management attributed to higher earnings and working-capital movements, including rebate-payment timing.
Heron Would Broaden The Revenue Base
CorMedix announced an agreement Monday to buy substantially all of Heron Therapeutics' assets. Todisco said the portfolio would reduce dependence on DefenCath for cash flow and growth.
The company expects those products to contribute about $125 million–$150 million in pro forma 2027 revenue, roughly doubling its non-DefenCath revenue base. It anticipates closing in the first quarter of 2027 and expects annualized operating cost savings of $45 million–$60 million by year-end.
The proposed purchase includes ZYNRELEF and APONVIE for perioperative care, plus CINVANTI and SUSTOL for hematology and oncology supportive care. Up to $55 million of consideration depends on ZYNRELEF reaching 2028 sales milestones.
CorMedix is also preparing for a possible expanded REZZAYO indication to prevent invasive fungal disease. The FDA granted priority review, with a target decision in the first quarter of 2027; management anticipates promotional efforts in the second half if approved.
CorMedix anticipates updating investors on DefenCath's revenue outlook in early 2027, once customer pricing and expected utilization are more visible.
Sources
- 8-K Filing — CorMedix Inc. (CRMD) — SEC EDGAR
- Exhibit ea031221101ex99-1.htm — CorMedix Inc. 8-K exhibit — SEC EDGAR